T Cell Sciences Highlights VRI's Adjuvant Technology In Merger To Form Avant
Executive Summary
Avant Immunotherapeutics, created from the merger of T Cell Sciences and Virus Research Institute, expects to seek partners to fund Phase III trials of T Cell's lead complement inhibitor, TP10, in cardiac surgery and vaccines for influenza and H. pylori using VRI's Micromer adjuvant technology.